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Abstract
Objective: Mutations in leucine-rich repeat kinase 2 (LRRK2) pose a significant
genetic risk in familial and sporadic Parkinson’s disease (PD). R1441 mutation
(R1441G/C) in its GTPase domain is found in familial PD. How LRRK2 inter-
acts with synaptic proteins, and its role in dopamine (DA) homeostasis and syn-
aptic vesicle recycling remain unclear. Methods: To explore the pathogenic
effects of LRRK2R1441G mutation on nigrostriatal synaptic nerve terminals
and locomotor activity, we generated C57BL/6N mice with homozygous
LRRK2R1441G knockin (KI) mutation, and examined for early changes in nigro-
striatal region, striatal synaptosomal [3H]-DA uptake and locomotor activity
after reserpine-induced DA depletion. Results: Under normal conditions,
mutant mice showed no differences, (1) in amount and morphology of nigro-
striatal DA neurons and neurites, (2) tyrosine hydroxylase (TH), DA uptake
transporter (DAT), vesicular monoamine transporter-2 (VMAT2) expression in
striatum, (3) COX IV, LC3B, Beclin-1 expression in midbrain, (4) LRRK2
expression in total cell lysate from whole brain, (5) a-synuclein, ubiquitin, and
tau protein immunostaining in midbrain, (6) locomotor activity, compared to
wild-type controls. However, after a single intraperitoneal reserpine dose, striatal
synaptosomes from young 3-month-old mutant mice demonstrated significantly
lower DA uptake with impaired locomotor activity and significantly slower
recovery from the effects of reserpine. Interpretation: Although no abnormal
phenotype was observed in mutant LRRK2R1441G mice, the KI mutation
increases vulnerability to reserpine-induced striatal DA depletion and perturbed
DA homeostasis resulting in presynaptic dysfunction and locomotor deficits with
impaired recovery from reserpine. This subtle nigrostriatal synaptic vulnerability
may reflect one of the earliest pathogenic processes in LRRK2-associated PD.
Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disease, characterized clinically by
bradykinesia, rigidity, resting tremor, and pathologically
by an irreversible loss of dopaminergic (DA) neurons in
substantia nigra pars compacta (SNpc). The underlying
mechanism of DA neuronal loss remains unclear but
there is evidence to indicate that striatal presynaptic dys-
function associated with defective DA uptake and turn-
over is observed in patients at the early stages of PD.1–3
DA reuptake and sequestration into synaptic vesicles at
striatal nerve terminals facilitate tonically active DA
release.4 Perturbation of DA recycling impairing intracel-
lular DA content and synaptic plasticity has been previ-
ously observed in experimental mouse models carrying
specific gene mutation associated with familial PD.5–7
Most cases of PD occur sporadically and are idiopathic,
but causal or predisposing genes have been identified in
familial cases.8 Leucine-rich repeat kinase 2 (LRRK2)
mutations pose the commonest genetic risk in both familial
and sporadic PD.9,10 Three variants of single amino acid
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substitution at R1441 residue (R1441G/C/H) of LRRK2 in
the highly conserved GTPase domain have been described.11
Of these, R1441G substitution is one of the commonest
mutations in LRRK2-associated PD,12,13 and has been
found in over 13% of Spanish cases from the Basque region.14
LRRK2 is involved in diverse neuronal functions15,16
and is highly expressed in striatum enriched with DA
nerve terminals where its expression level is even higher
than that in SNpc which contains their DA cell bodies.17
LRRK2 interacts with various synaptic proteins.18,19 Its
mutations cause abnormal synaptic dopamine neurotrans-
mission in both LRRK2 knockin and transgenic animal
models.20–22 Increased DA turnover was observed in
human asymptomatic LRRK2 mutation carriers,23 indicat-
ing that perturbation of DA homeostasis may be one of
the early events associated with pathogenic LRRK2 muta-
tion. However, how LRRK2R1441G mutation affects synap-
tic DA homeostasis remains unclear. We hypothesize that
LRRK2 plays a regulatory role in presynaptic terminals by
modulating DA recycling processes, and such synaptic
dysfunction associated with R1441G mutation contributes
to the degeneration of nigrostriatal dopaminergic neurons
and motor deficits in PD.
Here, we generated homozygous LRRK2R1441G knockin
(KI/KI) mice to examine for potential pathophysiological
changes in the dopaminergic nigrostriatal pathway. We
also explored the susceptibility of our young LRRK2
mutant mice to striatal DA depletion and impaired DA
recycling after a single dose of intraperitoneal reserpine, a
reversible inhibitor of the vesicular monoamine trans-
porter-2 (VMAT2).
Materials and Methods
Generation of LRRK2R1441G knockin mouse
A targeting cassette spanning exons 28–32 was con-
structed based on a BAC clone of wild-type mouse Lrrk2
gene (bMQ406i17). A point mutation (c. 4321C>G) was
created by mutagenesis, and a neomycin resistance cas-
sette (Neo) flanked by two FRT sites was inserted for
positive selection. The targeting cassette was electroporat-
ed into mouse embryonic stem (ES) cells (129/S6), and
the colonies with the correct homologous recombination
were selected by neomycin and verified by Southern blot.
The targeting cassette introduced two NcoI restriction
sites. Thus, NcoI digestion resulted in fragments with dif-
ferent lengths for wild-type and targeted alleles. These
were detected by two external probes (Fig. 1A). Positive
ES cell colonies with one copy of correctly targeted allele
were injected into blastocysts (C57BL/6N) to obtain chi-
meric mice. Neo was subsequently removed by breeding
with Flipper mice. The resultant heterozygous knockin
(KI/WT) mice were maintained under the C57BL/6N
mouse background by backcrossed to C57BL/6N mice for
seven generations and intercrossed to generate homozy-
gous knockin (KI/KI) mice and wild-type littermate con-
trols (WT/WT). The mice were maintained as KI/KI and
WT/WT. The primers are listed in Table 1. Only male
mice were used in subsequent experiments.
Mouse husbandry and genotyping
All mice were maintained in the Laboratory Animal Unit,
University of Hong Kong with accreditation through the
Association for Assessment and Accreditation of Laboratory
Animal care international (AAALAC). For genotyping, DNA
was extracted from ear clips by incubation in 100 lL PBND
buffer (50 mmol/L KCl; 10 mmol/L Tris-HCl, pH 8.0;
2.5 mmol/L MgCl2; 0.1 mg/mL Gelatin; 0.45% (v/v) Noni-
det P40; 0.45% (v/v) Tween20) with 1 mg/mL proteinase K
at 55°C overnight. After boiling for 5 min, the supernatant
was used for genotyping by PCR (Fig. 1A and Table 1).
Locomotor activity test
Locomotor activity of mice was monitored using open-
field tests.24 Briefly, the mice were allowed to acclimatize
in the behavioral testing room 3 days before the tests.
The locomotor recording was started immediately after
the mice were placed in the center of the plastic arena
(26 9 26 9 40 cm) of the test chamber adapted under
dim light. The mice were allowed to move freely and
tracked for 60 min (EthoVision3.0, Noldus Information
Technology, Wageningen, the Netherlands). The tests
were applied similarly to all the parallel groups. Move-
ment duration and distance moved of each mouse was
recorded 2 days prior to and 1 day after reserpine
(Sigma-Aldrich, St. Louis, MO) [1 mg/kg, intraperitoneal
(i.p.)] treatment. Recovery from reserpine treatment was
monitored for up to 14 days after injection.
Histology
For morphological examination of nigrostriatal neural
network, mice were perfused with cold PBS followed by
4% PFA under anesthesia. Whole brain was removed and
postfixed in 4% PFA at 4°C overnight. After dehydration
by exposure to serial dilutions of ethanol, the brain was
cleared by xylene before paraffin infiltration. Coronal sec-
tions (10 lm thick) were cut through the midbrain
(including substantia nigra) or striatum and horizontal
sections (10 lm thick) through the cerebellum. For
immunohistochemistry, endogenous peroxidase activity
was blocked by 3% H2O2. After blocking with TBS con-
taining 5% normal serum and 5% BSA for 1 h at room
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temperature, sections were incubated with primary anti-
body at 4°C overnight and then a secondary antibody
conjugated to HRP. The resultant color development of
DAB was monitored under the microscope.25 Stained
slides were dehydrated, cleared by xylene, and mounted
with Histomount (Invitrogen, Carlsbad, CA). The primary
antibodies were: anti-DAT (1:50, Santa-Cruz Biotechnology
#sc-32258), anti-TH (1:500, Millipore #AB318), anti-a-syn-
uclein (1:200, Cell Signaling #4179), anti-tau46 (1:400, Cell
Signaling #4019), anti-ubiquitin (1:400, Cell Signaling
#3933). Dopaminergic neuronal cell bodies from five
consecutive sections stained with TH at the comparable
SNpc region from three individual mice in each group
were counted under blinded conditions by two different
researchers independently. Striatal density was assessed
using ImageJ software26,27 (http://rsbweb.nih.gov/ij/plu-
gins/track/track.html) to measure TH staining density at
the comparable striatal region from four consecutive sec-
tions taken from three individual mice in each group.
Western blot
Striatum and midbrain were dissected and homogenized
in cold lysis buffer containing: 50 mmol/L Tris-Cl, pH
7.4, 150 mmol/L NaCl, 1% sodium deoxycholate,
1 mmol/L EDTA, 1% Triton X-100, 1 mmol/L phenyl-
methylsulfonyl fluoride, supplemented with protease
inhibitor cocktail. Lysates were clarified by centrifugation
at 4°C for 15 min at 13,500 g. Protein concentration was
determined by the Bradford assay. Equal amounts of pro-
tein were boiled for 10 min at 95°C in sample buffer con-
taining: 62.5 mmol/L Tris, pH 6.8, 100 mmol/L DTT, 2%
SDS, 10% glycerol, and 0.002% bromophenol blue. Sam-
ples were electrophoresed in 12% SDS-polyacrylamide
gels and transferred onto nitrocellulose membranes.
Resulting blot were blocked with 5% nonfat skimmed
Table 1. Primer sequences for embryonic stem (ES) cell colony
screening and mouse genotyping.
Objective Primer sequences
50 probe synthesis F: 50-GCTGGAGGAGTCGAGAGTTC-30
R: 50-GCATGGTGTGCTATAATCC-30
30 probe synthesis F: 50-CGCCGTTCACTTCCTAAATG-30
R: 50-GCATATAGATAAGAACCGGTAC-30
Routine genotyping F: 50-ACGCTGCTGTGTCACACGGTT-30
R: 50-TCCGAAGCTTTGCCAGCGCAT-30
Sequencing 50-ACGCTGCTGTGTCACACGGTT-30
Figure 1. Generation of LRRK2R1441G knockin mouse. (A) Gene targeting and confirmation strategy. N = NcoI. Neo = neomycin resistance cassette.
(B) Verification of correct gene targeting (Southern blot), LRRK2 point mutation sequencing (c. 4321 C>G), and genotyping. (C) LRRK2 protein
expression was not altered in KI/KI mouse (9 weeks, whole brain lysate; N = 4). Data are presented as mean + SEM. ns: not significant by unpaired
Student’s t-test.
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milk in TBS and probed with antibodies against LC3B
(1:1000, Cell Signaling, Danvers, MA; #3868, 14/16 kD),
Beclin-1 (1:1000, Cell Signaling #3495, 60 kD), COX IV
(1:2000, Abcam, Cambridge, MA; #ab16056, 17 kD) gly-
cosylated DAT (1:500, Santa-Cruz Biotechnology, Santa
Cruz Biotechnology, CA; #sc-32258, 80 kD), nonglycosy-
lated DAT (1:1000, Santa-Cruz Biotechnology #sc-10042,
50 kD), TH (1:2000, Millipore, Bedford, MA; #MAB318,
60 kD), a-synuclein (1:1000, Cell Signaling #417, 18 kD),
Tau46 (1:1000, Cell Signaling #4019, 50–80 kD), Ubiquitin
(1:1000, Cell Signaling #3933), Neuronal Class III b-Tubu-
lin (Tuj1) (1:2000, Covance, Princeton, NJ; #MRB-435P,
50 kD), Actin (1:500, Santa-Cruz Biotechnology #sc-1615,
43 kD), VMAT2 (1:500, Santa-Cruz Biotechnology #sc-
7721R, 63 kD), Synaptophysin (1:2000, Cell Signaling
#D35E4, 38 kD). For chemiluminescence detection, blots
were incubated with HRP-conjugated secondary antibodies
followed by ECL-plus substrate detection. Immunoblots
were quantified by computerized scanning densitometry.
Synaptosomal [3H]-dopamine uptake assay
Synaptosomal [3H]-DA uptake assay was performed as
previously described with slight modifications.28–30
Briefly, 5 lg synaptosomes were prewarmed and incu-
bated in 200 lL of Krebs–Ringer buffer (120 mmol/L
NaCl; 4.8 mmol/L KCl; 1.3 mmol/L CaCl2; 1.2 mmol/L
MgSO4; 1.2 mmol/L KH2PO4; 25 mmol/L NaHCO3;
6 mmol/L glucose; pH 7.6) containing 100 nmol/L [3H]-
DA for 5 min at 37°C. Nonspecific uptake was deter-
mined by a parallel negative control in the presence of
10 lM nomifensine (DAT inhibitor). To test the effect of
reserpine, synaptosomes and reserpine (vehicle control,
50 nmol/L, 500 nmol/L) were prewarmed for 2.5 min at
37°C. The reaction was stopped by adding 200 lL cold
Krebs–Ringer buffer and mixture was passed through a
UniFilterⓇ-96 GF/C filter (PerkinElmer, Norwalk, CT;
#6005174) by unifilter-96 harvester (Packard), followed
by three washes of cold Krebs–Ringer buffer. The filter
was dried at 55°C overnight, and [3H] radioactivity
(count per minute, cpm) was measured using the Top-
CountNXTTM counter (Packard). Each treatment group
was measured at least in duplicate for each experiment.
Statistics
Statistical analyses were carried out using the Prism
(GraphPad Software Inc., San Diego, CA). Data are
expressed as mean  standard error mean (SEM). The
number of animals and independent experiments are
indicated in the figure legends. Student’s t-test was used
to compare levels of protein expression among groups.
Two-way ANOVA with post hoc Bonferroni multiple
comparison tests were used to compare [3H]-DA uptake
and locomotor activity in the open-field tests. Differences
between groups were considered significant at P < 0.05.
Results
Generation of the LRRK2R1441G knockin (KI)
mouse
We generated homozygous LRRK2R1441G KI mice carrying a
point mutation in exon 31 (c.4321C>G) that causes
R1441G substitution in LRRK2 protein. The Southern blot
result showed the 13.7 kb band representing the WT allele
detected by 50 and 30 probes, and the 7.3 kb band by 50
probe and 7.7 kb band by 30 probe representing the KI allele
(Fig. 1A). The presence of mutant murine genomic DNA
was verified by Southern blot, genotyping, and sequencing
(Fig. 1B). The mutant LRRK2 expression is controlled by
its endogenous promoter (Fig. 1A). Expression of mutant
LRRK2 protein in KI/KI mouse brain was similar to wild-
type protein in WT/WT control mouse brain (Fig. 1C).
Striatum and SNpc were morphologically
normal in aged mutant mice
There was no apparent phenotypic difference in KI/KI
mice as compared with WT/WT. They were fertile and
had normal body weight, brain size, and locomotor activ-
ity (Figs 4 and S2). Histological examination revealed sim-
ilar levels of TH and DAT in SNpc and striatum at
3 months and 18–22 months (Fig. 2A and B; Fig. S3).
There were no significant differences in number of TH+
DA neurons in SNpc and TH staining intensity in stria-
tum (KI/KI vs. WT/WT mice at 18–22 months – Fig. 2C).
The two independent methods – counting total TH+ cells
in SNpc and striatal neurite density gave consistent results,
showing no significant difference in the neuronal numbers
and neurite density in KI/KI and WT/WT mice, consistent
with our Western blot results on TH protein expression.
Similarly, glycosylated and nonglycosylated DAT had
comparable expression levels in KI/KI and WT/WT in
both striatum and midbrain at age 18 months (Fig. 2D).
No apparent difference in degree of protein
aggregation in aged mutant mice midbrain
compared with wild-type controls
Histological studies revealed similar ubiquitin and tau
expression in midbrain, and a-synuclein in midbrain and
cerebellum at 18–22 months (Fig. 3A). These three pro-
teins had comparable expression levels in KI/KI and WT/
WT in midbrain at age 18 months (Western blot;
Fig. 3B) or at 22 months (immunohistochemistry;
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Fig. 3A). There were no differences in expression levels of
COX IV (mitochondrial marker), LC3B and Beclin-1
(autophagy markers) between KI/KI and WT/WT young
mice (Fig. S4) and aging mice (Fig. 3B).
Mutant mice were more susceptible to
reserpine-induced locomotor deficits, and
recovered slower
LRRK2 KI/KI mice demonstrated similar locomotor activ-
ity as WT/WT at age of 3 and 12 months. Older mice
had less distance moved and slower velocity in both WT/
WT and KI/KI groups (P < 0.05; Fig. 4), but such
decrease did not involve a significant interacting effect
between genotype (i.e. R1441G) and aging.
Reserpine (1 mg/kg, i.p.) significantly decreased locomo-
tor activity in both 3-month-old WT/WT and KI/KI mice
(distance moved; velocity; movement duration: all
P < 0.05; N = 8) at 2 days posttreatment, (Fig. 5). How-
ever, compared to WT/WT mice, mutant mice exhibited a
significantly greater decrease in these locomotor parameters
after reserpine injection (WT/WT vs. KI/KI; all P < 0.05;
Fig. 5). Both WT/WT and KI/KI started to recover from
their locomotor deficits after day 2 post reserpine. For WT/
WT mice, the locomotor parameters recovered to pretreat-
ment levels by day 14 post reserpine. However, KI/KI mice
had consistently lower locomotor activity at all three time
points (i.e., day 2, 7, and 14 post-reserpine), as compared
with WT/WT controls (all P < 0.05; Fig. 5).
Young mutant mice exhibited more severe
reduction in striatal synaptosomal DA
uptake than wild-type controls after
reserpine treatment
Total [3H]-DA uptake was performed in striatal synapto-
somal isolates extracted from both 3 and 18 months old
mice. Both WT/WT and KI/KI synaptosomes had similar
Figure 2. Aged LRRK2R1441G knockin mice have similar amounts of DA neurons and neurites compared to wild-type mice. (A, B) No apparent
difference in the expression pattern of TH and DAT in SNpc and striatum between WT/WT and KI/KI mice at 18–22 months (N = 3). Scale = 150 lm
in (A) and 200 lm in (B). (C) Statistical analysis of TH+ DA neurons numbers and neurite intensity of stained SNpc and striatum revealed no
significant difference in combination of TH expression and cell count (unpaired Student’s t-test, N = 3). (D) Western blot showed similar expression
levels of TH and DAT (glycosylated and nonglycosylated) in striatum and midbrain in WT/WT and KI/KI mice at 3 and 18 months of age (N = 3).
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levels of DA uptake at their corresponding ages (Fig. 6A).
Similar to the locomotor activity, there was no significant
interacting effect between genotype (i.e. R1441G) and
aging on [3H]-DA uptake between 3 and 18 month-old
mice (Fig. 6A).
Following reserpine treatment, [3H]-DA uptake into
striatal synaptosomes (50 nmol/L reserpine) was signifi-
cantly lower (-12%) in isolates from KI/KI mice com-
pared with WT/WT even at age 3 months (WT/WT:
6583  283 cpm; KI/KI: 5786  157 cpm; N = 10;
P < 0.05; Fig. 6B). A dose-dependent decrease in DA
uptake was observed with reserpine treatment, but the
difference in DA uptake between KI/KI and WT/WT
became insignificant at the excessive dose of 500 nmol/
L (Fig. 6B). Using two-way ANOVA analysis, the
mutant genotype (P < 0.01) and reserpine (P < 0.01)
were independently associated with reduction in DA
uptake.
Figure 3. Aged LRRK2R1441G knockin mice have similar a-synuclein, ubiquitin, and tau expression patterns compared to those of WT/WT mice.
(A) No apparent difference in the expression patterns of a-synuclein in midbrain and cerebellum, and the similar expression patterns of ubiquitin
and tau in midbrain between WT/WT and KI/KI mice at 18–22 months (N = 3). SNpc substantia nigra pars compacta; SNr substantia nigra pars
reticulata. Scale = 500 lm in 49 magnification and 150 lm in 209 magnification. (B) Western blot showed similar expression level of a-
synuclein, ubiquitin, tau and autophagy makers LC3B and Beclin-1 in midbrain of WT/WT and KI/KI mice at 18 months of age (N = 3).
204 ª 2014 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Mutant LRRK2 Mice Liable to Dopamine Depletion H.-F. Liu et al.
Striatal DAT and VMAT2 protein expression, which
may affect total synaptosomal DA uptake, were similar
between KI/KI and WT/WT mice (Figs 2D, 6C).
Discussion
We describe here a mutant LRRK2R1441G KI/KI mouse
expressing physiological levels of the variant protein.
Unlike mice overexpressing mutant LRRK2 which showed
obvious parkinsonian phenotype,31,32 LRRK2R1441G KI/KI
mutation had no apparent abnormal phenotype, or
abnormal parameters in dopaminergic function and pro-
tein aggregation even in aged mice (Figs 3, 4, 6A). The
number and morphology of DA neurons were similar
between KI/KI and WT/WT in aged mice up to
22 months (Fig. 2). This is in contrast to the
LRRK2R1441G transgenic mouse which showed severe loss
of DA dendrites and morphological abnormalities of DA
neurons in SNpc at 9–10 month of age, age-dependent
motor deficits, and decreased spontaneous DA release.32
Nevertheless, the R1441G mutant protein in our mutant
mice is expressed at physiological level comparable to the
WT protein, and we demonstrated that these mutant KI/
KI mice were more susceptible to synaptic DA depletion
and motor deficits associated with impaired DA uptake
induced by reserpine. We believe that the KI/KI mice
more closely mimic the disease condition in humans.
Reserpine produces behavioral deficits resembling PD
motor symptoms33 through its catecholamine-depleting
effects on nerve terminals.34 It inhibits vesicular monoamine
Figure 4. LRRK2R1441G knockin mice have similar locomotor activities as WT/WT in open-field test. Locomotor activity of KI/KI mice was not
significantly different from WT/WT at 3 and 12 months of age, although an age-dependent decrease was observed. #P < 0.05; two-way ANOVA
with post hoc Bonferroni multiple comparison tests. (3 months: N = 20; 12 months: N = 15; mean + SEM).
Figure 5. LRRK2R1441G knockin mice are more susceptible to reserpine-induced locomotor deficits. KI/KI mice injected with reserpine (1 mg/kg)
demonstrated more severe impairment in locomotor activity compared to that of WT/WT at 3 months of age. Both mutant and control mice
recovered after treatment, and KI/KI mice recovered much more slowly than WT/WT mice. *P < 0.05; **P < 0.01; ***P < 0.001; two-way
ANOVA with post hoc Bonferroni multiple comparison tests; N = 8; mean  SEM.
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transferase-2 (VMAT2) and blocks sequestration of cyto-
solic DA into synaptic vesicles. With reserpine (50 nmol/
L), [3H]-DA uptake was significantly reduced in young
KI/KI striatal synaptosomes (Fig. 6B). This was not due to
expression level of DAT or VMAT2 as their protein
expression was not altered in striatum (Fig. 2D, 6C). The
higher dose of reserpine (500 nmol/L) caused an even
greater reduction in synaptosomal DA uptake. However,
the difference in [3H]-DA uptake between KI/KI and WT/
WT mice was not statistically significant (Fig. 6B) because
the toxic effects of high dose reserpine probably over-
whelmed the effects of the LRRK2 mutation on DA
uptake. Extracellular [3H]-DA uptake through DAT into
synaptosomes is suppressed by abnormally high cytosolic
DA concentration induced by reserpine.35 High concentra-
tions of cytosolic DA can reduce DAT function in vitro.36
The significantly decreased [3H]-DA uptake in reserpine-
treated KI/KI striatal synaptosomes (Fig. 6B) indicates
that LRRK2R1441G mutation potentiates DA depletion in
striatum by suppressing uptake of extracellular DA in
mutant presynaptic terminals. The significantly reduced
locomotor activity in young KI/KI mice after reserpine
(Fig. 5) indicates that these mutant mice are more sensi-
tive to perturbed DA homeostasis by reserpine than WT/
WT. Furthermore, these young mutant mice recovered
significantly slower in terms of their locomotor activity
suggesting that they are more vulnerable to further stress
on their DA uptake system, compared to WT/WT mice
which recovered back to baseline levels within 2 weeks.
The functional deficits in locomotor activity and synapto-
somal DA uptake in these young mutant mice which
recovered slower after a single stressor event on DA
uptake may have important pathogenic implications in
terms of adverse cumulative effects over their lifespan.
Despite the apparent lack of abnormal phenotype in
our mutant mice, our results show that a functional sus-
ceptibility can still exist. This is illustrated in asymptom-
atic human LRRK2 mutation carriers who have abnormal
putaminal DA turnover shown using positron emission
tomography neuroimaging techniques.23 Similarly, DA
neurons and locomotor activity appeared normal in
LRRK2R1441C KI mice, but they had impaired DA neuro-
transmission.20 The higher susceptibility to reserpine in
our KI/KI mice indicates very early striatal synaptic dys-
function before any structural abnormalities could possi-
bly be observed. Our results implicate the notion that the
pathogenic process in PD starts from dysfunction of stria-
tal nerve terminals proceeding in a retrograde dying-back
process37–39 rather than a compensatory mechanism to
counteract early dopaminergic neuronal loss,40 because
there was no significant striatal neuronal loss observed
even in our aged mutant mice. How presynaptic defects
and abnormal DA homeostasis lead to neuronal cell death
associated with LRRK2 mutations require further investi-
gations.
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Supporting Information
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Figure S1. LRRK2 protein structure and PD related
R1441 mutations.
Figure S2. Gross morphology and body weight curve.
Figure S3 Young LRRK2R1441G mutant mice have similar
amount of DA neuron and neurites compared to wild
type.
Figure S4. Expression level of related proteins.
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